Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021
- Corporate and Finance
Jul 6, 2021
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
- COVID-19
Jun 30, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021
- Statement
- COVID-19
Jun 30, 2021
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre
- Statement
- COVID-19
Jun 22, 2021
Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum
- Corporate and Finance
Jun 17, 2021
Novavax to Participate in National Vaccine Advisory Committee Meeting
- Corporate and Finance
Jun 17, 2021
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
- COVID-19
- Seasonal Influenza
Jun 14, 2021
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
- COVID-19
Jun 14, 2021
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
- COVID-19
Jun 11, 2021
Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters
- Corporate and Finance
Jun 9, 2021
Novavax to Participate in Panel at BIO Digital 2021
- COVID-19
Jun 7, 2021
Novavax to Participate in Jefferies Virtual Healthcare Conference
- COVID-19
May 27, 2021
Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update
- COVID-19
May 24, 2021
Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea
- COVID-19
May 22, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants in the United Kingdom
- Statement
- COVID-19
May 22, 2021
Complete Trial Results Manuscript of Novavax COVID-19 Investigational Vaccine Posted to Preprint Server medRxiv
- Statement
- COVID-19
May 21, 2021
Novavax Statement on Participation in Mix-and-Match COVID-19 Vaccine Booster Trial in the United Kingdom
- Statement
- COVID-19
May 21, 2021
Novavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration
- Corporate and Finance
May 21, 2021
Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
- Corporate and Finance
May 10, 2021
Novavax Statement on Updated PREVENT-19 Trial Protocol
- Statement
- COVID-19
May 10, 2021
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
- COVID-19
- Seasonal Influenza
May 10, 2021
Novavax Statement on Ministry of Health, Labour and Welfare’s Announcement Regarding Procurement from Takeda of NVX-CoV2373 for Japan
- Statement
- COVID-19
May 7, 2021
Novavax Statement in Opposition to the WTO TRIPS Waiver
- Statement
- COVID-19
May 7, 2021
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
- COVID-19
May 6, 2021
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant

May 5, 2021

Show per page